शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
PARADEEPNSEParadeep Phosphates Limited· Fertilizers & AgrochemicalsHighNeutral
Announced Mon, 2 Feb, 2026 · 18:59 IST

Q3 FY26 results: revenue 5,748 cr, 9M PAT up 71%; MD re-appointed

Revenue growth above 20%Profit growth above 25%Results restatedExceptional itemEmphasis of matterResults View source PDFExplain this filing

PARADEEP · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-2.0%Reaction day
₹132.69
prior close
₹134.43
announcement price
After-mkt
timing
Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+2.9%-5.0% vs market
Fertilizers peers, median of 19sector+0.7%-2.7% vs sector

On the reaction day the stock moved 5.0 pts less than Nifty Smallcap 250 and 2.7 pts less than its Fertilizers peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-4.0
10m
-5.3
15m
-5.7
30m
-6.3
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-2.0+2.9-5.0+0.7-2.7
Next day
-1.3+3.7-5.0+1.3-2.6
2d
-5.9+2.7-8.6-0.0-5.9
3d
-7.2+2.3-9.5-1.3-5.9
4d
-2.8+4.9-7.7+1.2-4.0
5d
-5.0+5.4-10.4+1.6-6.6
1w
-6.9+4.8-11.6+0.3-7.2
15d
-13.0+2.7-15.7-3.7-9.2
1m
-17.5-1.7-15.8-9.7-7.7
2m
-12.7-4.0-8.6-12.4-0.3
3m
-4.4+9.0-13.4-1.4-3.1
UpDownMarket · Nifty Smallcap 250Sector · Fertilizers peers, median of 19Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved Q3 and 9M FY26 results, restated for MCFL merger. Q3 revenue 5,748.67 cr, up 15% YoY; 9M revenue 17,124.37 cr, up 34%. Q3 PAT 182.05 cr vs 209.28 cr (down 13% due to 41.30 cr Labour Code exceptional charge). 9M PAT up 71% to 841.24 cr. EPS Q3 at 1.76. MD Suresh Krishnan re-appointed for 3 years; K K Rajeev Nambiar named Joint MD from April 1, 2026. BSR and Co issued unmodified review with emphasis on merger restatement.

Likely market impact

Strong 9M growth on restated basis (revenue up 34%, PAT up 71%). Q3 dip is from one-time Labour Code charge. Leadership continuity maintained.